BIIB34:BVMF
Biogen Inc BDR
188,28 R$
0,00%
(0,00) 1D
21 სექ, 16:31:47 GMT-3 · BRL
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for BIIB34...
Mkt. cap
32,49 მლრდ.
Avg. vol.
4,00
Volume
0,00
52-wk high
191,00 R$
52-wk low
128,69 R$
Shares outstanding
147,75 მლნ.
No. of employees
8 ათ.
Mkt. cap
32,49 მლრდ.
Avg. vol.
4,00
Volume
0,00
52-wk high
191,00 R$
52-wk low
128,69 R$
Shares outstanding
147,75 მლნ.
No. of employees
8 ათ.
News stories
From web sources and news partners
AD HOC NEWS
·
1 დღის წინ
Biogen stock after-hours at EUR 195.34: minus 1.44 percent versus prior close
Investing.com Canada
·
1 დღის წინ
Biogen reports 52-week litifilimab data for lupus treatment By Investing.com
Profile
Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, United States specializing in the treatment of neurological diseases. The company's primary products are dimethyl fumarate, diroximel fumarate, interferon beta-1a, peginterferon beta-1a, and natalizumab, all for the treatment of multiple sclerosis; nusinersen for the treatment of spinal muscular atrophy; omaveloxolone for the treatment of Friedreich's ataxia; tofersen for the treatment of ALS; and dimethyl fumarate for the treatment of severe plaque psoriasis. The company also produces 5 biosimilars and has collaborations with Genentech for several drugs.
The company is ranked 424th on the Fortune 500 and 845th on the Forbes Global 2000. Wikipedia
About Biogen Inc BDR
CEOქრის ვიბახერ
Employees7,5 ათ.
Founded1978
Headquartersკემბრიჯი, მასაჩუსეტსი, ამერიკის შეერთებული შტატები
Sector-
Websitebiogen.com